PMC:7646269 / 1366-2110 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T12","span":{"begin":35,"end":48},"obj":"Disease"},{"id":"T13","span":{"begin":134,"end":158},"obj":"Disease"},{"id":"T14","span":{"begin":160,"end":168},"obj":"Disease"},{"id":"T15","span":{"begin":198,"end":217},"obj":"Disease"},{"id":"T16","span":{"begin":331,"end":339},"obj":"Disease"},{"id":"T17","span":{"begin":446,"end":454},"obj":"Disease"},{"id":"T18","span":{"begin":524,"end":537},"obj":"Disease"},{"id":"T19","span":{"begin":555,"end":563},"obj":"Disease"},{"id":"T20","span":{"begin":660,"end":668},"obj":"Disease"},{"id":"T21","span":{"begin":702,"end":715},"obj":"Disease"}],"attributes":[{"id":"A12","pred":"mondo_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/MONDO_0005657"},{"id":"A13","pred":"mondo_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A14","pred":"mondo_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A15","pred":"mondo_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/MONDO_0021113"},{"id":"A16","pred":"mondo_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A17","pred":"mondo_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A18","pred":"mondo_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/MONDO_0005657"},{"id":"A19","pred":"mondo_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A20","pred":"mondo_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A21","pred":"mondo_id","subj":"T21","obj":"http://purl.obolibrary.org/obo/MONDO_0005657"}],"text":"1 INTRODUCTION\nInvasive pulmonary aspergillosis (IPA) has been reported in critically ill patients in the ICU. 1 , 2 Patients with coronavirus disease‐2019 (COVID‐19) may develop acute hypoxemic respiratory failure and are at high risk of requiring mechanical ventilation with prolonged ICU stays. Further, patients with severe COVID‐19 may be administered high‐dose glucocorticoids. Hence, there is a theoretical risk of IPA in patients with COVID‐19 due to combined known risk factors. However, there are scant data on aspergillosis in patients with COVID‐19. 3 , 4 , 5 , 6 The aim of the study was to describe the clinical features of critically ill COVID‐19‐infected patients with pulmonary aspergillosis at a New York City hospital."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T9","span":{"begin":55,"end":58},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T10","span":{"begin":403,"end":404},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T11","span":{"begin":565,"end":571},"obj":"http://purl.obolibrary.org/obo/CLO_0001302"},{"id":"T12","span":{"begin":587,"end":590},"obj":"http://purl.obolibrary.org/obo/PR_000001343"},{"id":"T13","span":{"begin":719,"end":720},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"1 INTRODUCTION\nInvasive pulmonary aspergillosis (IPA) has been reported in critically ill patients in the ICU. 1 , 2 Patients with coronavirus disease‐2019 (COVID‐19) may develop acute hypoxemic respiratory failure and are at high risk of requiring mechanical ventilation with prolonged ICU stays. Further, patients with severe COVID‐19 may be administered high‐dose glucocorticoids. Hence, there is a theoretical risk of IPA in patients with COVID‐19 due to combined known risk factors. However, there are scant data on aspergillosis in patients with COVID‐19. 3 , 4 , 5 , 6 The aim of the study was to describe the clinical features of critically ill COVID‐19‐infected patients with pulmonary aspergillosis at a New York City hospital."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T8","span":{"begin":50,"end":53},"obj":"Chemical"},{"id":"T10","span":{"begin":370,"end":385},"obj":"Chemical"},{"id":"T11","span":{"begin":425,"end":428},"obj":"Chemical"}],"attributes":[{"id":"A8","pred":"chebi_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/CHEBI_17824"},{"id":"A9","pred":"chebi_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/CHEBI_30802"},{"id":"A10","pred":"chebi_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/CHEBI_24261"},{"id":"A11","pred":"chebi_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/CHEBI_17824"},{"id":"A12","pred":"chebi_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/CHEBI_30802"}],"text":"1 INTRODUCTION\nInvasive pulmonary aspergillosis (IPA) has been reported in critically ill patients in the ICU. 1 , 2 Patients with coronavirus disease‐2019 (COVID‐19) may develop acute hypoxemic respiratory failure and are at high risk of requiring mechanical ventilation with prolonged ICU stays. Further, patients with severe COVID‐19 may be administered high‐dose glucocorticoids. Hence, there is a theoretical risk of IPA in patients with COVID‐19 due to combined known risk factors. However, there are scant data on aspergillosis in patients with COVID‐19. 3 , 4 , 5 , 6 The aim of the study was to describe the clinical features of critically ill COVID‐19‐infected patients with pulmonary aspergillosis at a New York City hospital."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T5","span":{"begin":16,"end":48},"obj":"Phenotype"},{"id":"T6","span":{"begin":50,"end":53},"obj":"Phenotype"},{"id":"T7","span":{"begin":198,"end":217},"obj":"Phenotype"},{"id":"T8","span":{"begin":425,"end":428},"obj":"Phenotype"}],"attributes":[{"id":"A5","pred":"hp_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/HP_0020103"},{"id":"A6","pred":"hp_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/HP_0020103"},{"id":"A7","pred":"hp_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/HP_0002878"},{"id":"A8","pred":"hp_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/HP_0020103"}],"text":"1 INTRODUCTION\nInvasive pulmonary aspergillosis (IPA) has been reported in critically ill patients in the ICU. 1 , 2 Patients with coronavirus disease‐2019 (COVID‐19) may develop acute hypoxemic respiratory failure and are at high risk of requiring mechanical ventilation with prolonged ICU stays. Further, patients with severe COVID‐19 may be administered high‐dose glucocorticoids. Hence, there is a theoretical risk of IPA in patients with COVID‐19 due to combined known risk factors. However, there are scant data on aspergillosis in patients with COVID‐19. 3 , 4 , 5 , 6 The aim of the study was to describe the clinical features of critically ill COVID‐19‐infected patients with pulmonary aspergillosis at a New York City hospital."}

{"project":"LitCovid-sentences","denotations":[{"id":"T22","span":{"begin":0,"end":15},"obj":"Sentence"},{"id":"T23","span":{"begin":16,"end":111},"obj":"Sentence"},{"id":"T24","span":{"begin":112,"end":300},"obj":"Sentence"},{"id":"T25","span":{"begin":301,"end":386},"obj":"Sentence"},{"id":"T26","span":{"begin":387,"end":490},"obj":"Sentence"},{"id":"T27","span":{"begin":491,"end":564},"obj":"Sentence"},{"id":"T28","span":{"begin":565,"end":744},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"1 INTRODUCTION\nInvasive pulmonary aspergillosis (IPA) has been reported in critically ill patients in the ICU. 1 , 2 Patients with coronavirus disease‐2019 (COVID‐19) may develop acute hypoxemic respiratory failure and are at high risk of requiring mechanical ventilation with prolonged ICU stays. Further, patients with severe COVID‐19 may be administered high‐dose glucocorticoids. Hence, there is a theoretical risk of IPA in patients with COVID‐19 due to combined known risk factors. However, there are scant data on aspergillosis in patients with COVID‐19. 3 , 4 , 5 , 6 The aim of the study was to describe the clinical features of critically ill COVID‐19‐infected patients with pulmonary aspergillosis at a New York City hospital."}

{"project":"LitCovid-PubTator","denotations":[{"id":"80","span":{"begin":91,"end":99},"obj":"Species"},{"id":"81","span":{"begin":120,"end":128},"obj":"Species"},{"id":"82","span":{"begin":310,"end":318},"obj":"Species"},{"id":"83","span":{"begin":432,"end":440},"obj":"Species"},{"id":"84","span":{"begin":541,"end":549},"obj":"Species"},{"id":"85","span":{"begin":678,"end":686},"obj":"Species"},{"id":"86","span":{"begin":16,"end":48},"obj":"Disease"},{"id":"87","span":{"begin":76,"end":90},"obj":"Disease"},{"id":"88","span":{"begin":134,"end":158},"obj":"Disease"},{"id":"89","span":{"begin":160,"end":168},"obj":"Disease"},{"id":"90","span":{"begin":198,"end":217},"obj":"Disease"},{"id":"91","span":{"begin":331,"end":339},"obj":"Disease"},{"id":"92","span":{"begin":446,"end":454},"obj":"Disease"},{"id":"93","span":{"begin":524,"end":537},"obj":"Disease"},{"id":"94","span":{"begin":555,"end":563},"obj":"Disease"},{"id":"95","span":{"begin":645,"end":659},"obj":"Disease"},{"id":"96","span":{"begin":660,"end":677},"obj":"Disease"},{"id":"97","span":{"begin":692,"end":715},"obj":"Disease"}],"attributes":[{"id":"A80","pred":"tao:has_database_id","subj":"80","obj":"Tax:9606"},{"id":"A81","pred":"tao:has_database_id","subj":"81","obj":"Tax:9606"},{"id":"A82","pred":"tao:has_database_id","subj":"82","obj":"Tax:9606"},{"id":"A83","pred":"tao:has_database_id","subj":"83","obj":"Tax:9606"},{"id":"A84","pred":"tao:has_database_id","subj":"84","obj":"Tax:9606"},{"id":"A85","pred":"tao:has_database_id","subj":"85","obj":"Tax:9606"},{"id":"A86","pred":"tao:has_database_id","subj":"86","obj":"MESH:D055744"},{"id":"A87","pred":"tao:has_database_id","subj":"87","obj":"MESH:D016638"},{"id":"A88","pred":"tao:has_database_id","subj":"88","obj":"MESH:C000657245"},{"id":"A89","pred":"tao:has_database_id","subj":"89","obj":"MESH:C000657245"},{"id":"A90","pred":"tao:has_database_id","subj":"90","obj":"MESH:D012131"},{"id":"A91","pred":"tao:has_database_id","subj":"91","obj":"MESH:C000657245"},{"id":"A92","pred":"tao:has_database_id","subj":"92","obj":"MESH:C000657245"},{"id":"A93","pred":"tao:has_database_id","subj":"93","obj":"MESH:D001228"},{"id":"A94","pred":"tao:has_database_id","subj":"94","obj":"MESH:C000657245"},{"id":"A95","pred":"tao:has_database_id","subj":"95","obj":"MESH:D016638"},{"id":"A96","pred":"tao:has_database_id","subj":"96","obj":"MESH:C000657245"},{"id":"A97","pred":"tao:has_database_id","subj":"97","obj":"MESH:D055732"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"1 INTRODUCTION\nInvasive pulmonary aspergillosis (IPA) has been reported in critically ill patients in the ICU. 1 , 2 Patients with coronavirus disease‐2019 (COVID‐19) may develop acute hypoxemic respiratory failure and are at high risk of requiring mechanical ventilation with prolonged ICU stays. Further, patients with severe COVID‐19 may be administered high‐dose glucocorticoids. Hence, there is a theoretical risk of IPA in patients with COVID‐19 due to combined known risk factors. However, there are scant data on aspergillosis in patients with COVID‐19. 3 , 4 , 5 , 6 The aim of the study was to describe the clinical features of critically ill COVID‐19‐infected patients with pulmonary aspergillosis at a New York City hospital."}